Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ampligen as therapy for early-onset COVID-19

Next Previous
X
Search
Trial Profile

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ampligen as therapy for early-onset COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors AIM ImmunoTech

    • Most Recent Events

    • 30 Sep 2021 New trial record
    • 28 Sep 2021 According to an AIM ImmunoTech media release, the company has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19. This study include exploratory endpoints that could support company's recently filed provisional patent application.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top